CLVLY (Clinuvel Pharmaceuticals) EPS (Basic) : $0.48 (TTM As of Jun. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals EPS (Basic)?

Clinuvel Pharmaceuticals's basic earnings per share (Basic EPS) for the six months ended in Jun. 2024 was $0.33. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.48.

Clinuvel Pharmaceuticals's EPS (Diluted) for the six months ended in Jun. 2024 was $0.32. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.47.

Clinuvel Pharmaceuticals's EPS without NRI for the six months ended in Jun. 2024 was $0.32. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was 0.47.

During the past 12 months, Clinuvel Pharmaceuticals's average EPS without NRIGrowth Rate was 18.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was 13.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 14.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Clinuvel Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 32.10% per year. The lowest was -120.60% per year. And the median was 13.00% per year.

Clinuvel Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Clinuvel Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals EPS (Basic) Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

EPS (Basic)

Get a 7-Day Free Trial

0.23

0.38

0.30

0.42

0.48

Clinuvel Pharmaceuticals Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EPS (Basic)	Get a 7-Day Free Trial															0.21	0.16	0.26	0.15	0.33

Clinuvel Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Clinuvel Pharmaceuticals's Basic EPS for the fiscal year that ended in Jun. 2024 is calculated as

Basic EPS (A: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(23.663	-	0)	/	49.834
	=	0.47

Clinuvel Pharmaceuticals's Basic EPS for the quarter that ended in Jun. 2024 is calculated as

Basic EPS (Q: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(16.401	-	0)	/	50.121
	=	0.33

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.48

Clinuvel Pharmaceuticals (OTCPK:CLVLY) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Clinuvel Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLY) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

CLVLF:USA UR9:Germany UR9:Germany UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.